US · SRRK · BIOTECHNOLOGY
Scholar Rock Holding Corporation (SRRK) intrinsic value and stock valuation
$48.13as of 2026-11-21 · Mkt cap 5.74B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Scholar Rock Holding Corporation DCF and intrinsic value
InvestorsCraft values SRRK with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SRRK’s statements →
Scholar Rock Holding Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Xenon Pharmaceuticals Inc. (XENE) $37.04
- Kiniksa Pharmaceuticals International, plc (KNSA) $93.90
- Adaptive Biotechnologies Corporation (ADPT) $27.93
- Legend Biotech Corporation (LEGN) $15.25
- IDEAYA Biosciences, Inc. (IDYA) $25.56
- Disc Medicine, Inc. (IRON) $75.14
- Beam Therapeutics Inc. (BEAM) $20.90
- Mineralys Therapeutics, Inc. (MLYS) $13.66
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $33.2M | $18.8M |
| Operating income | -$-384.64M | -$-252.05M | -$-171.29M | -$-134.37M | -$-129.92M |
| Net income | -$-377.94M | -$-246.29M | -$-165.79M | -$-134.5M | -$-131.8M |
| EPSd | -$-3.3M | -$-2.47M | -$-2.18M | -$-2.26M | -$-3.59M |
| Operating cash flow | -$-300.04M | -$-200.95M | -$-145.23M | -$-132.69M | -$-126.79M |
| Capital expenditure | -$-600K | -$-100K | -$-70K | -$-1.06M | -$-5.25M |
| Free cash flow | -$-300.64M | -$-201.05M | -$-145.3M | -$-133.76M | -$-132.04M |
| Total assets | $404.3M | $474.9M | $311M | $358.2M | $304.4M |
| Total debt | $108.9M | $65.1M | $61.8M | $69.4M | $84.5M |
| Net debt | -$-214.61M | -$-112.75M | -$-40.04M | -$-33.88M | -$-128.37M |
| Total equity | $245.5M | $368.6M | $225.2M | $260.2M | $172.1M |
| Cash and short-term investments | $367.6M | $437.3M | $279.9M | $315.4M | $253M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $33.2M | $18.8M |
| Cost of revenue | $208.4M | $1.94M | $2.84M | $123M | $108.5M |
| Gross profit | -$-208.44M | -$-1.94M | -$-2.84M | -$-89.85M | -$-89.65M |
| Research and development expenses | $208.4M | $182.6M | $119.1M | $124.4M | $108.5M |
| Selling, general and administrative expenses | $176.2M | $67.5M | $49.4M | $42.6M | $40.3M |
| Other expenses | -$-208.44M | $0.00 | $0.00 | -$-122.54M | -$-108.47M |
| Operating expenses | $176.2M | $250.1M | $168.5M | $44.5M | $40.3M |
| Cost and expenses | $384.6M | $252.1M | $171.3M | $167.6M | $148.7M |
| Interest income | $13.9M | $12.7M | $0.00 | $0.00 | $0.00 |
| Interest expense | $6.89M | $6.84M | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.66M | $1.94M | $2.84M | $2.99M | $2.63M |
| Ebitda | -$-369.39M | -$-237.52M | -$-162.94M | -$-129.48M | -$-129.17M |
| Operating income | -$-384.64M | -$-252.05M | -$-171.29M | -$-134.37M | -$-129.92M |
| Total other income/expenses, net | $6.71M | $5.76M | $5.51M | -$-130K | -$-1.88M |
| Income before tax | -$-377.94M | -$-246.29M | -$-165.79M | -$-134.5M | -$-131.8M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-377.94M | -$-246.29M | -$-165.79M | -$-134.5M | -$-131.8M |
| Weighted average shares outstanding | $114.7M | $99.8M | $76M | $59.6M | $36.7M |
| Weighted average diluted shares outstanding | $114.7M | $99.8M | $76M | $59.6M | $36.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $367.6M | $437.3M | $279.9M | $315.4M | $253M |
| Net receivables | $0.00 | $2.15M | $1.08M | $2.73M | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $385.2M | $451.2M | $288.2M | $328M | $265.3M |
| Property, plant and equipment, net | $12.1M | $18.4M | $16M | $25.9M | $35M |
| Goodwill and intangible assets | $0.00 | $2.4M | $4.07M | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.5M |
| Total non-current assets | $19.1M | $23.8M | $22.8M | $30.1M | $39.1M |
| Total assets | $404.3M | $474.9M | $311M | $358.2M | $304.4M |
| Accounts payable | $10.3M | $10.1M | $3.46M | $3.99M | $4.43M |
| Short-term debt | $5.55M | $5.77M | $8.74M | $7.85M | $16.4M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $33.2M |
| Total current liabilities | $55.4M | $46.9M | $32.7M | $36.4M | $64.3M |
| Long-term debt | $103.4M | $59.4M | $53.1M | $61.5M | $68.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $103.4M | $59.4M | $53.1M | $61.5M | $68.1M |
| Capital lease obligations | $3.66M | $15M | $11.8M | $19.7M | $27.1M |
| Total liabilities | $158.8M | $106.3M | $85.8M | $97.9M | $132.4M |
| Common stock | $110K | $90K | $80K | $50K | $40K |
| Retained earnings | -$-1.3B | -$-922.72M | -$-676.42M | -$-510.63M | -$-376.13M |
| Accumulated other comprehensive income (loss) | $90K | $160K | $90K | -$-880K | -$-40K |
| Total equity | $245.5M | $368.6M | $225.2M | $260.2M | $172.1M |
| Total investments | $44M | $259.4M | $178.1M | $212.1M | $42.7M |
| Total debt | $108.9M | $65.1M | $61.8M | $69.4M | $84.5M |
| Net debt | -$-214.61M | -$-112.75M | -$-40.04M | -$-33.88M | -$-128.37M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-377.94M | -$-246.29M | -$-165.79M | -$-134.5M | -$-131.8M |
| Depreciation and amortization | $1.66M | $1.94M | $2.84M | $2.99M | $2.63M |
| Stock-based compensation | $75.6M | $36.6M | $27.1M | $27.7M | $23.2M |
| Change in working capital | -$-1.05M | $6.59M | -$-10.61M | -$-34.39M | -$-28.44M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $210K | $6.63M | -$-530K | -$-250K | $1.02M |
| Net cash provided by operating activities | -$-300.04M | -$-200.95M | -$-145.23M | -$-132.69M | -$-126.79M |
| Investments in property, plant and equipment | -$-600K | -$-100K | -$-70K | -$-1.06M | -$-5.25M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $218.7M | -$-76.06M | $41.1M | -$-171.7M | $134.3M |
| Common stock issued | $179.3M | $324.4M | $97.7M | $195.3M | $13.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $228.4M | $353M | $102.6M | $194.8M | $45M |
| Net change in cash | $147.1M | $76M | -$-1.51M | -$-109.56M | $52.5M |
| Cash at end of period | $327.3M | $180.3M | $104.3M | $105.8M | $215.3M |
| Operating cash flow | -$-300.04M | -$-200.95M | -$-145.23M | -$-132.69M | -$-126.79M |
| Capital expenditure | -$-600K | -$-100K | -$-70K | -$-1.06M | -$-5.25M |
| Free cash flow | -$-300.64M | -$-201.05M | -$-145.3M | -$-133.76M | -$-132.04M |
Line items
Line items
Line items
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
- CEO
- David L. Hallal
- Employees
- 289
- Beta
- 0.68
Explore
Frequently asked questions
What is the intrinsic value of Scholar Rock Holding Corporation (SRRK)?
InvestorsCraft does not currently publish an intrinsic value for SRRK. How the IC value is calculated.
Is SRRK undervalued?
InvestorsCraft does not publish an undervaluation signal for SRRK at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.